Checkpoint inhibitors such as pembrolizumab or nivolumab, which inhibit PD-1 in combination with other chemotherapeutic agents or targeted therapy in HER2-positive BC, deserve further investigation. The gene discussed is ERBB2; the disease is breast cancer.